US20250017840
2025-01-16
Human necessities
A61K8/64
Overview: The patent application introduces a novel senotherapy peptide aimed at addressing cellular senescence, which contributes to tissue aging and related diseases. This peptide suppresses the interaction between p53 and FOXO4, facilitating the release of p53 from the nucleus to mitochondria, thereby inducing apoptosis in senescent cells. The primary focus is on selectively targeting and inducing apoptosis in skin senescent cells.
Background: Cellular senescence leads to tissue aging and the secretion of inflammatory factors known as senescence-associated secretory phenotype (SASP). This process is linked to various age-related diseases. Current treatments, like senolytics and senomorphics, aim to remove or restore function in these cells but often come with limitations such as side effects. The development of targeted senotherapeutics is crucial for effectively managing tissue aging and related diseases.
Invention Details: The disclosed peptide contains the amino acid sequence SEQ ID NO: 1, which has a stronger binding affinity to p53 compared to FOXO4. This allows p53 to exit the nucleus and move to mitochondria, initiating apoptosis specifically in skin senescent cells. The invention also includes compositions that use this peptide to improve skin wrinkles and enhance MMP-1 suppressive activity.
Applications: The peptide can be used in various compositions for improving skin wrinkles and inducing apoptosis of skin senescent cells. It is proposed as an active ingredient in formulations designed for senotherapy, offering a potential treatment for age-related skin conditions by targeting senescent cells without affecting healthy cells.
Composition and Usage: The peptide is recommended for inclusion in compositions at concentrations ranging from 0.001% to 1% by weight. These compositions can be tailored for different therapeutic applications, including skin wrinkle improvement and overall senotherapy, providing a targeted approach to managing cellular aging.